John Anson, Paul Kenny
Oxford Gene Technology has announced that it has appointed John Anson as CEO, who previously served as executive VP of research and development. He will be replacing Mike Evans, who has become a non-executive director of OGT's board
In addition, OGT has appointed Paul Kenny as executive VP of regulatory and medical affairs. Kenny previously served as head of regulatory affairs at The Binding Site.